// App-Quantinova.ai

P432 : Barriers to prescribing anti-TNF therapy in inflammatory bowel disease (IBD) across newly industrialised emerging market countries: an analysis of the ‘EXPLORE’ study

Researchers

Presenter

  • B D Ye

Principal Investigators

  • J K Yamamoto Furusho

  • M Rana Qasim Khan

  • O Fadeeva

  • D Demuth

  • J Qian

  • I L Khalif

  • T Chia-Hung

  • M Toruner

  • A H Othman

  • W Chan

  • E Ponce de Leon

  • M Guennec

  • C Sison

  • E Uberti Foppa

  • A Armuzzi

Medical Centers

  • University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, seoul, Korea- Republic Of

  • National Institute of Medical Sciences and Nutrition, Department of Gastroenterolgy, Mexico city, Mexico

  • Takeda Pharmaceutical International AG Singapore branch, Singapore, Singapore

  • Takeda International–UK Branch, London, UK

  • Peking Union Medical College Hospital, Beijing, China

  • Federal State Budgetary Institution ‘State Scientific Center of Coloproctology n.a. A.N. Rizhikh’ of the Ministry of Public Health of Russian Federation, Inflammatory and Functional Bowel Diseases Research Unit, Moscow, Russian Federation

  • National Yang-Ming University, Taipei, Taiwan

  • Ankara University School of Medicine, Pharmacology, Ankara, Turkey

  • King Khalid University Hospital , King Saud University, Department of Medicine, Riyadh, Saudi Arabia

  • Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

  • Hepatology, Fundacion Cardioinfantil-Instituto de Cardiologia, Bogota, Colombia

  • IQVIA, Saint Ouen, France

  • IQVIA, Makati City, Philippines

  • PRA Health Sciences, Global Medical Affairs – Research, Europe Development Centre, Takeda International – UK Branch, London, UK

  • IBD Unit, Presidio Columbus Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy

Locations

  • Republic of South Korea

  • Mexico

  • Singapore

  • United Kingdom

  • China

  • Russia

  • Taiwan

  • Turkey

  • Saudi Arabia

  • Colombia

  • France

  • Philippines

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved